Organon & Co. (OGN) Borrowing debt
- Total debt · latest quarter (USD): Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2026-06-30..
- Net cash · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2026-06-30..
- Debt / assets · latest quarter: Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2026-06-30..
Borrowing debt
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total debt · latest quarter (USD) | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Net cash · latest quarter | (m) | Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Debt / assets · latest quarter | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Borrowing debt due within one year | (m) | Long-term Debt, Current Maturities |
| Borrowing debt due after one year | 8.48B USD | Long-term Debt, Excluding Current Maturities |
| Commercial paper | (m) | |
| Cash and current securities | (m) | Cash and Cash Equivalents, at Carrying Value |
| Borrowing debt | (m) | Long-term Debt, Current Maturities · Long-term Debt, Excluding Current Maturities |
| Total assets | 13.18B USD | Assets |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total debt | Net cash / debt | Borrowing debt due within one year (USD) | Borrowing debt due after one year (USD) | Commercial paper (USD) | Cash and current securities (USD) | Total assets (USD) | Debt / assets |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | (m) | $8.48B | (m) | (m) | $13.18B | (m) |
| 2026-03-31 | (m) | (m) | (m) | $8.55B | (m) | (m) | $13.00B | (m) |
| 2025-12-31 | (m) | (m) | (m) | $8.63B | (m) | (m) | $12.87B | (m) |
| 2025-09-30 | (m) | (m) | (m) | $8.78B | (m) | (m) | $13.55B | (m) |
| 2025-06-30 | (m) | (m) | (m) | $8.78B | (m) | (m) | $13.50B | (m) |
| 2025-03-31 | (m) | (m) | $20.00M | $8.94B | (m) | (m) | $13.16B | (m) |
| 2024-12-31 | (m) | (m) | $20.00M | $8.86B | (m) | (m) | $13.10B | (m) |
| 2024-09-30 | (m) | (m) | $10.00M | $8.74B | (m) | (m) | $12.75B | (m) |
| 2024-06-30 | (m) | (m) | $9.00M | $8.65B | (m) | (m) | $12.15B | (m) |
| 2024-03-31 | (m) | (m) | $9.00M | $8.71B | (m) | (m) | $11.89B | (m) |
| 2023-12-31 | (m) | (m) | $9.00M | $8.75B | (m) | (m) | $12.06B | (m) |
| 2023-09-30 | (m) | (m) | $8.00M | $8.65B | (m) | (m) | $11.01B | (m) |
| 2023-06-30 | (m) | (m) | $8.00M | $8.72B | (m) | (m) | $10.98B | (m) |
| 2023-03-31 | (m) | (m) | $8.00M | $8.70B | (m) | (m) | $10.76B | (m) |
| 2022-12-31 | (m) | (m) | $8.00M | $8.90B | (m) | (m) | $10.96B | (m) |
| 2022-09-30 | (m) | (m) | $8.00M | $8.69B | (m) | (m) | $10.44B | (m) |
| 2022-06-30 | (m) | (m) | $9.00M | $8.88B | (m) | (m) | $10.61B | (m) |
| 2022-03-31 | (m) | (m) | $9.00M | $9.09B | (m) | (m) | $10.60B | (m) |
| 2021-12-31 | (m) | (m) | $9.00M | $9.13B | (m) | (m) | $10.68B | (m) |
| 2021-09-30 | (m) | (m) | $39.00M | $9.26B | (m) | (m) | $11.34B | (m) |
| 2021-06-30 | (m) | (m) | $39.00M | $9.31B | (m) | (m) | $10.91B | (m) |
| 2020-12-31 | (m) | (m) | $0.00 | $0.00 | (m) | (m) | $10.11B | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |